Apricot BIO is a first-time launcher of a Functional Precision Oncology platform performing deep molecular phenotyping of drug responses for personalised therapy recommendations for early to late-stage clinical decision-making leading to more precise, evidenced-based recommendations for doctors.
Products, services, technology
Service delivers multiplex drug response profiling of patient biopsies at subcellular, single-cell, and multicellular scales, enabling high spatial resolution across large areas, no need for conjugated antibodies, identifies non-responders that typically make trials fail, unprecedented scalability
Cooperation possibilities
Drug discovery companies: to accelerate lead compound characterisation (e.g. Molecular Glue Degraders)
Hospitals/healthcare providers: for drug response profiling of ex vivo patient biopsies to improve treatment outcomes
Large pharma: to accelerate drug development (pre/clinical stages)
- http://www.Apricotx.com
- +41 44 63 53 123
- Send an email
- Michael Zering
Some insights
Through our functional precision oncology spin-off from University of Zurich, our goal is 2-fold: to increase patient eligibility to personalised cancer treatment and increase evidenced-based drug recommendations for patients who do not show a clinical response to standard of care (SOC) therapy
Our unique ability to assess whether a drug is effective, and also to understand why - by linking variability in drug responses to specific cellular states, sensitivity and resistance. This yields predictive effective combinations and likely clinical outcomes with a turnaround time of just 5–7 days
APx is fortunate to have highly skilled colleagues that transitioned from PhD studies in life sciences and systems biology at Pelkmans Lab to commercialising our start-up. Deep knowledge of the 4iDRP platform is achieved, underpinned with a diverse entrepreneurial leadership team.
At work? My children would say they don't quite understand what I do.
Senior leaders at Tier 1 Pharma companies focused on drug discovery, reducing R&D costs for large scale projects.
SME Biotechs developing molecules (e.g. molecular glue degraders)
World class labs needing a platform that will connect the dots for precision medicine